Fig. 3. Duration of response* in 32 patients receiving G-atezo-len (INV-assessed, efficacy-evaluable population; 36-month cutoff: 7 October 2020).

*Duration of response was defined as time from the first occurrence of a documented objective response to the time of disease progression or relapse, as determined by the investigator on the basis of CT scans alone or death from any cause, whichever occurred first.